Phase 1a/1b study will evaluate NRM-823 as monotherapy and in combination with immune checkpoint inhibition in patients with locally-advanced or metastat...
Bristol Myers Squibb to provide idecabtagene vicleucel (ide-cel) for Dispatch’s planned U.S. Phase 1 study, expected to initiate in 2026 Collabo...
First patient dosed, with topline results expected in 2027 pHalcon-EoE-201 is the first large, well-controlled clinical trial of an acid secretory tre...
Recurrent respiratory papillomatosis (RRP) is a rare HPV-related disease of the respiratory tract with significant unmet need INO-3107 previously rece...
Collaboration will leverage AI-powered neural analysis and Compass' expertise in psychedelic drug development to advance new therapies for mental health ...
Pfizer Inc. announced that it has filed a lawsuit against Metsera, Inc., its Board of Directors, and Novo Nordisk, S.A. in the Delaware Court of Chancery...
Integrated sterile sampling and PUPSIT solutions streamline bioprocessing, enhance flexibility, and reduce risk while accelerating in-process decis...
First Global Supply Chain Solutions Company to Achieve ISO 21973 Certification, Ensuring Highest Transport Safety, Traceability, and Integrity Standards ...
Biocare Medical, a global leader in immunohistochemistry instrumentation, antibodies and reagents, and Hamamatsu Corporation, a worldwide innovator in im...
ChemDiv, a global provider of integrated drug discovery solutions, announced the extension of its Chemistry, Manufacturing and Controls (CMC) servi...
Expected to be immediately accretive to Adjusted Earnings Per Share (EPS)¹ after close Attractive return profile given high growth and strong margi...
New Synlight-Pure™ Kit together with Syncell’s Microscoop® Mint platform achieves high-specificity subcellular proteomic discovery with 25 ...
Avance Clinical, the award-winning Australian led, global CRO built exclusively to service the clinical research needs of biotech companies, announced th...
siRNA candidate EMP-012 in phase I for treatment of COPD EMP-012 targets a distinct inflammatory pathway with enhanced potency and longer dose int...
© 2026 Biopharma Boardroom. All Rights Reserved.
